This past September Nanoligent technology was featured in the health section of the Spanish national newspaper ABC. The capacity to selectivity kill metastatic stem cells, and thus, reduce the overall toxicity of the treatment is highlighted as the main strength of Nanoligent’s technology.
There are currently no drugs on the market that selectively remove metastatic stem cells, so it is estimated that the medicine will have a high clinical impact once the clinical trials are passed. As Nanoligent researchers stated during the interview, the research published in the journal «EMBO Molecular Medicine» opens a new path towards metastasis prevention in colorectal cancer.